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Abstract
Background and Purpose: Abnormal hypometabolism is common in the brain parenchyma
surrounding developmental venous anomalies (DVAs), although the degree of DVA-associated
hypometabolism (DVAAh) has not been quantitatively analyzed. In this study, we demonstrate
a simple method for the measurement of DVAAh and test the hypothesis that DVAs are
associated with a quantifiable decrement in metabolic activity.
Materials and Methods: Measurements of DVAAh using ratios of standardized uptake values
(SUVs) and comparison to a normal database were performed on a cohort of 25 patients (12
male, 13 female), 14 to 76 years old, with a total of 28 DVAs (20 with DVAAh, seven with
isometabolic activity, and one with hypermetabolic activity).
Results: Qualitative classification of none, mild, moderate, and severe DVAAh corresponded to
quantitative measurements of DVAAh of 1 ± 3%, 12 ± 7%, 18 ± 6%, and 37 ± 6%, respectively. A
statistically significant linear correlation between DVAAh and age was observed (P = 0.003),
with a 3% reduction in metabolic activity per decade. A statistically significant linear
correlation between DVAAh and DVA size was observed (P = 0.01), with a 4% reduction in
metabolic activity per each 1 cm in the longest dimension. The SUVDVA-based measures of
DVAAh correlated (P = 0.001) with measures derived from comparison with a standardized
database.
Conclusion: We present a simple method for the quantitative measurement of DVAAh using
ratios of SUVs, and find that this quantitative analysis is consistent with a qualitative
classification. We find that 54% (15 of 28) of DVAs are associated with a greater than 10%
decrease in metabolic activity.
Categories: Neurology, Radiology
Keywords: developmental venous anomaly, dva, dva-associated hypometabolism, pet imaging
Introduction
Developmental venous anomalies (DVAs) are the most common vascular malformation
identified on brain imaging [1]. Traditionally, DVAs have been considered benign in that they
are not commonly associated with symptoms, and evidence suggested a low frequency of
adverse effects [2]. However, several studies report an association between MRI signal
abnormalities within brain parenchyma in the drainage territory of 12.5% [3] to 28.3% [4] of
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DVAs in adults. These studies show an increased prevalence of MR signal abnormalities in
older patients, which raises the possibility of increasing brain parenchymal abnormality with
age that may then become symptomatic. Possible mechanisms of DVA pathophysiology include
venous congestion [5], hypoperfusion [6], and venous hypertension leading to ischemia and
microhemorrhage [7-8]. Multiple imaging examples of parenchymal and perfusion
abnormalities associated with DVAs have been documented [9]. We previously showed the
presence of a mild, moderate, or severe degree of DVA-associated hypometabolism (DVAAh) in
72% (18 of 25) of the DVAs in patients who had a known DVA and FDG-PET imaging [10]. A
quantitative analysis of DVAAh, however, has not been reported. In this study, we present a
method for the measurement of DVAAh and test the hypothesis that DVAs are associated with a
quantifiable decrement in metabolic activity that is associated with DVA size and patient age.
Materials And Methods
Patient population
A total of 25 patients with 28 distinct DVAs were included for analysis in this study. A summary
of the DVA characteristics and associated findings is presented in Table 1. In a prior study [10],
we reported on 22 of these patients with a total of 25 DVAs, which are now included in the
current study as well as three additional cases. The prior study was a qualitative analysis based
on visual inspection. This current study employs a quantitative analysis using methods that are
easily employed in clinical practice. This study was performed at a tertiary care academic
medical center for adult and pediatric patients and was approved by the Partners Healthcare
Institutional Review Board (approval #2013P001673). Informed patient consent was obtained at
the time of treatment. Criteria for inclusion in the study were the following: 1) patients with at
least one cerebral or cerebellar DVA identified by MRI and reconfirmed by a neuroradiologist; 2)
positive confirmation of the DVA, as defined by the presence of radially converging dilated
medullary veins (caput medusa) converging to a large transparenchymal vein that drains into a
deep or superficial vein; and 3) availability of an FDG-PET scan performed within one year of
the MRI examination demonstrating the DVA. Cases were excluded if any of the following
criteria were present: 1) PET or MRI findings suggestive of a neurodegenerative disease, or 2) a
confounding lesion, such as a tumor, in the region of the DVA or the anatomically equivalent
contralateral cortex.
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Summary of Characteristics of All Patients and DVAs*​
Characteristic  
Total No. of patients 25
No. of DVAs per patient  
            1 22 (88%)
            2 3 (12%)
Age (years)  
            Mean ± SD 44.3 ± 19.4
            Range 14 - 76
Male, female sex 12 (48%), 13 (52%)
Degree of DVA-associated metabolic activity  
            Isometabolic 7 (25%)
            Hypometabolic 20 (71%)
                        Mild             12 (43%)
                        Moderate             5 (18%)
                        Severe             3 (11%)
            Hypermetabolic 1 (4%)
                        Mild             0 (0%)
                        Moderate             0 (0%)
                        Severe             1 (4%)
TABLE 1: Summary of Characteristics of All Patients and DVAs*
*Each DVA was counted separately in the three patients with multiple DVAs. Twenty-two of these 25 patients were qualitatively
presented in a prior study [10].
MR imaging
The included MR examinations were performed using a variety of imaging protocols that were
prescribed according to the clinical indication for the scan and have been described previously
[10]. Briefly, all MR imaging was performed at our institution using 1.5T (GE and Siemens), 3.0T
(GE and Siemens), and 7T (Siemens) scanners (General Electric Co., Boston, MA ) (Siemens
Healthcare, Malvern, PA). Post-contrast T1-weighted images, T2 images, and susceptibility-
weighted imaging (SWI) images were preferentially used for evaluation and confirmation of the
DVA.
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18F-fluorodeoxyglucose positron emission tomography (18F-
FDG-PET) imaging
All PET imaging was performed at our institution using a standard protocol as described
previously [10]. Briefly, imaging was obtained approximately 45 minutes following intravenous
injection of 5.0 mCi of 18F-fluorodeoxyglucose (FDG) using an ECAT HR+ scanner
(Siemens/CTI, Knoxville, TN) and 63 planes were acquired simultaneously over a 15.5 cm field
of view in 3D mode. Attenuation correction was performed using a transmission scan obtained
with a 68Ge source, and a maximum likelihood reconstruction method was used, yielding
images with an in-plane resolution of approximately 4.6 mm. All patients were screened with
fingerstick blood glucose measurement; PET imaging was not performed in those patients with
blood glucose greater than 150 mg/dl.
Image analysis
The MR and PET images were co-registered using Syngo.via and Syngo TrueD systems (Siemens
Healthcare, Malvern, PA) software, which was then used for the measurement of the average
standardized uptake value (SUV) in a 1 cm3 spherical region of interest (ROI) around the
visually determined lesions and in the anatomically equivalent contralateral brain region. The
SUV represents the radioactivity concentration observed in an ROI relative to the hypothetical
case of homogeneous distribution of the injected radioactivity across the entire body of the
patient. In this study, SUVDVA is defined as the mean SUV from the region of the DVA divided
by the mean SUV in the anatomically equivalent contralateral region. The size of each DVA was
measured as the single longest dimension of the aberrant vasculature. The qualitative
characterization of the degree of metabolic abnormality (mild, moderate, or severe
hypometabolism; isometabolism; or mild, moderate, or severe hypermetabolism) was
determined by a consensus of the authors.
Database comparison
All PET studies were compared to a normal control patient database with Syngo.via software
using the Molecular Imaging Neurology workflow (Figure 1). The PET images were aligned with
an ensemble-average image derived from the normal database and automatically segmented. A
region corresponding to the DVA was manually selected in each case and the difference in
standard deviations compared to a normal database was recorded. Separate comparison
databases were used for younger subjects (age: 19-44) and older subjects (age: 46-79).
FIGURE 1: Representative axial MR (A), FDG-PET (B), and
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statistical map (C) of DVA-affected brain.
A) Post-contrast T1 image shows a DVA (white arrow) within the left cerebellar hemisphere. B)
FDG-PET demonstrates the DVAAh, qualitatively classified as severe, that corresponds to an
SUVR of 0.65. C) The statistical map graphically depicts the standard deviations of the
metabolic activity relative to a normal subject database. In this case, the auto-segmented
region (white outline) of the left cerebellum corresponds to -3.6 standard deviations from the
mean SUV in this region for normal controls.
Statistical analysis
Statistical analyses were performed using MATLAB (The MathWorks, Inc., Natick, MA, USA).
Differences less than the threshold of α = 0.05 were considered statistically significant. Analysis
of variance was used to identify statistically significant differences in SUVDVA among the
previously qualitatively-labeled groups. A linear regression model was used to determine if
there was a statistically significant correlation between SUVDVA and patient age, SUVDVA and
DVA size, and SUVDVA and the standard deviation from the mean SUV derived from a database
of normal subjects.
Results
The qualitative classification of none, mild, moderate, and severe DVAAh corresponded to a
mean ± standard deviation of 1 ± 3%, 12 ± 7%, 18 ± 6%, and 37 ± 6% decrease, respectively, in
the SUV measured on the side of the DVA compared to the anatomically equivalent
contralateral region. As shown in Figure 2, the mean SUVDVA for the severe DVAAh category
was found to be significantly different from the mean SUVDVA of all other qualitative DVAAh
designations (none and mild: P < 0.0001; moderate: P < 0.01). The mean SUVDVA for no DVAAh
was also found to be significantly different from the mean SUVDVA of all other qualitative
DVAAh designations (mild: P < 0.001; moderate and severe: P < 0.0001). There was no
statistical difference in the quantitative measures associated with moderate and mild DVAAh (P
= 0.1).
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FIGURE 2: SUV of DVA measurements for qualitative DVAAh
classification.
The SUVDVA was determined based on the mean SUV from the cortex drained by the DVA
divided by the mean SUV from the approximated anatomically equivalent region in the
contralateral brain. The previously defined "none", "mild", "moderate", and "severe" qualitative
degree of DVAAh correspond to a 1 ± 3%, 12 ± 7%, 18 ± 6%, and 37 ± 6% decrease,
respectively, in the SUV measured from the region of DVAAh compared to the contralateral
region. Asterisks indicate statistical significance: *P < 0.01, **P < 0.001, ***P < 0.0001.
Figures 3-5 depict all of the cases color-coded based on the qualitative DVAAh designations:
green for none, yellow for mild, orange for moderate, and red for severe. The cases of no (green)
DVAAh are centered on an SUVDVA of approximately one while the severe (red) DVAAh cases
are found only at an SUVDVA level of less than 0.7. In the one previously reported patient who
demonstrated severe DVA-associated hypermetabolism [10], the SUVDVA in the hypermetabolic
ROI was 3.6 (this anomalous case was not included in Figures 2-5 or any correlation analysis in
this study).
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FIGURE 3: SUV of DVA compared to patient age
The degree of DVAAh compared to the contralateral anatomic region (SUVDVA) were plotted as
a function of age (in years) for each DVA in the series. A linear regression (SUVDVA = -0.003 *
Age (years) + 1.0) was fit to the data, with R2 = 0.29; P = 0.003. No moderate (orange) or severe
(red) cases were seen in patients less than 50 years of age. The color of each point indicates
the qualitative degree of DVAAh compared to the contralateral anatomic region (none: green;
mild: yellow; moderate: orange; severe: red).
2016 Timerman et al. Cureus 8(9): e799. DOI 10.7759/cureus.799 7 of 12
FIGURE 4: SUV of DVA compared to DVA size.
The degree of DVAAh compared to the contralateral anatomic region (SUVDVA) were plotted as
a function of size (in cm) for each DVA. A linear regression (SUVDVA = -0.04 * Size (in cm) + 0.99)
was fit to the data, with R2 = 0.22; P = 0.01. The color of the plot point indicates the qualitative
degree of hypometabolism of the DVA compared to the contralateral brain region (none: green;
mild: yellow; moderate: orange; severe: red). The outlier measuring 5.6 cm in the "none" group
was not removed from the regression analysis and corresponds to a 24-year-old patient.
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FIGURE 5: SUV of DVA compared to standard deviations from
the mean.
The degree of DVAAh compared to the contralateral brain region (SUVDVA) was plotted as a
function of the standard deviations from the normal mean (SD) for each DVA. A linear regression
(SUVDVA = 0.02 * SD + 0.92) was fit to the data, with R2 = 0.34; P = 0.001. The color of the plot
point indicates the qualitative degree of hypometabolism of the DVA compared to the
contralateral anatomic region (none: green; mild: yellow; moderate: orange; severe: red). 
A statistically significant (P = 0.003, R2 = 0.29) linear correlation between SUVDVA-based
DVAAh and age was observed, with a 3% rate of decline in relative metabolic activity per
decade (Figure 3). Moderate (orange) or severe (red) cases were only seen in patients older than
50 years.
As shown in Figure 4, a statistically significant (P = 0.01, R2 = 0.22) linear correlation between
SUVDVA-based DVAAh and DVA size was observed, with a 4% rate of decline in metabolic
activity for each 1 cm in the longest dimension (lesions ranged between 0.9 and 6.1 cm long).
Within the no DVAAh (green) subgroup, six of seven DVAs were less than 3 cm in greatest
dimension, with a notable outlier measuring 5.6 cm. This patient with a 5.6 cm DVA was 24
years old. The mild (yellow) and moderate (orange) DVAAh cases ranged in size from < 1 cm to
4 cm, and all severe (red) DVAAh cases were > 3 cm (Figure 4). There was no statistically
significant association between DVA size and patient age (P = 0.52, data not shown).
There is a statistically significant (P = 0.001, R2 = 0.34) linear correlation between SUVDVA and
the standard deviation from the mean SUV derived from a database of normal subjects (Figure
5).
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Discussion
In this study, we describe a quantitative assessment of the degree of DVAAh, performed using a
method that may be employed in clinical practice. We used an SUVDVA analysis to compare
DVAAh between patients under the assumption that the injected radioactivity and body weight
components of the SUV formula are canceled out [11-13]. This method allowed us to quantify
the degree of DVAAh and quantitatively assess the visual classifications of mild, moderate, and
severe from our prior study. An advantage of using the SUVDVA as an objective measure of
altered metabolic activity in the drainage region of a DVA is the relative simplicity of this
analysis and consequent potential for clinical application of this method. Measurement of the
SUVDVA can be used to confirm a qualitative assessment of the degree of change in metabolic
activity in the region of a DVA. This quantitative measurement of DVAAh can be combined with
the patient’s clinical history to aid in the determination of how a DVA should be managed.
The worsening of DVAAh with increasing age could imply that the natural history of DVAs may
result in either increasing damage to adjacent brain parenchyma or possibly remodeling of
parenchyma away from the region with altered venous drainage. We find that no patients under
the age of 50 years old had more than a 20% reduction in SUVDVA, which complements findings
of increased MR abnormalities associated with DVAs in patients of older age in prior studies [3-
4]. However, the SUVDVA measurement of DVAAh in patients over 50 years old ranged from
severely decreased to nearly normal (0.56 to 0.97), suggesting that some DVAs tend to have an
increased degree of DVAAh than others. A prospective, longitudinal study would be ideal to
determine if progression of DVAAh exists on an individual patient level. Such an analysis would
require performing repeat FDG-PET imaging to measure the relatively small rate of change in
DVAAh, which, according to our data, is on the order of 3% per decade. Further research is also
necessary to determine if the suggested 50-year-old age threshold contributes to the
identification of patients in whom there is clinical concern that a DVA may be symptomatic.
Additional studies could also clarify if particular DVA morphology may predict the degree and
progression of DVAAh independent of patient age. One study of pediatric patients suggested
that the presence of deep venous drainage in DVAs may play an independent role in the
prediction of associated brain parenchymal signal abnormality [14].
Although there is an inverse relationship between DVAAh and DVA size in our data, there were
no clear thresholds between any of the qualitative groups based on size. This may indicate
that the measurement of the longest DVA dimension is not an optimal index of true DVA size,
the parameters for SUVDVA measurement could be redefined to more accurately represent
DVAAh, and/or that there are additional features and physiologic mechanisms that can
contribute to better prediction of which DVAs are associated with greater DVAAh than others.
Our results did not show a significant correlation between DVA size and patient age. However,
our analysis was limited to a retrospectively defined cohort of patients with PET imaging, as
this study was not designed to analyze for DVA growth. Consequently, the question of whether
or not DVAs enlarge with age remains to be answered. A comparison of DVA size to patient age
does not require the presence of PET imaging. A study testing such an association would likely
identify some patients with multiple longitudinal MR scans, enabling individualized size
comparisons over time. Of note, one 24-year-old patient with a DVA of 5.6 cm demonstrated
no DVAAh, which may be attributable to the relatively young age.
We also performed statistical parametric mapping in order to compare the difference in
metabolic activity in our cohort of patients compared to a database. This was done using
software that auto-aligned and auto-segmented the PET data for each patient, and
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subsequently, the region encompassing the DVA was manually selected. Although the auto-
alignment and auto-segmentation of brain regions were objective, the manual selection of the
region corresponding to the DVA was occasionally challenging given that some DVAs did not
respect standard anatomical divisions and DVAAh was, in some cases, represented in two or
more neighboring segments. Furthermore, for small DVAs, the segmented regions were
generally larger than the region affected with DVAAh; consequently, the measured number of
standard deviations from the baseline was underestimated by the inclusion of unaffected brain
parenchyma. However, despite these limitations, the correlation between this automated
measure of DVAAh and the SUVDVA-based measure of DVAAh was statistically significant.
There are several limitations of this study. The number of cases analyzed was limited by the
scarcity of patients with DVAs who also had FDG-PET imaging. To develop a robust measure of
the incidence of DVAAh, it will be necessary to reproduce these results in other patient cohorts.
The greater incidence of metabolic derangement and co-morbidities, particularly in older
patients, is a potential confounder that could contribute to the observed increase in DVAAh
severity. There are also limitations to the SUVDVA method for quantifying DVAAh [13]. Manual
selection of ROIs results in individually-biased results that may have suboptimal
reproducibility. To partially avoid user-bias, neuroradiologists can select ROIs on an MR scan
of the patient prior to registration with the PET study. Robust inter-user reproducibility has
been shown in other studies that specifically compared manual and automated selection of
SUV ROIs [15]. Image noise and limited resolution also affect the SUV measurement. Another
limitation of this study is the technique used to determine DVA size. The measurement for DVA
size was an estimate based on the largest dimension of the DVA in any plane. This approach to
characterizing DVA size is of limited accuracy and is not a robust assessment of the diversity of
DVA morphology. However, in the clinical setting, it is a practical method for estimating DVA
size. Overall, this quantitative approach could be a clinically useful supplement to the visually-
determined qualitative assessment of DVAAh. 
Conclusions
We find that quantitative analysis of DVAAh using SUVDVA is consistent with a visual,
qualitative assessment of DVAAh. We find that 54% (15 of 28) of DVAs are associated with a
greater than 10% decrease in metabolic activity as measured by SUVDVA measured from FDG-
PET. These results show that simple, quantitative measurements may be reliably used for
evaluation of metabolic abnormality associated with DVAs and may be helpful in classifying
patients that may warrant further examination or intervention. While we have demonstrated
that DVAs are associated with measurable hypometabolic activity, the short and long-term
clinical implications of this finding are not well understood. Further investigation into the
natural history of DVAs, including the evolution of DVAAh, is necessary to determine the
appropriate management of patients with DVAs.
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